GSK Licenses RA Drug from ChemoCentryx

GlaxoSmithKline has exercised its option to obtain an exclusive worldwide license to further develop and commercialize ChemoCentryx's investigational drug CCX354 for the treatment of rheumatoid arthritis . Full Story
Robson

Toronto, Canada

#1 May 6, 2012

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

ChemoCentryx Discussions

Title Updated Last By Comments
IPO Preview: ChemoCentryx (May '12) May '12 Robson 1
GSK licenses experimental arthritis treatment f... (May '12) May '12 Robson 1
GSK Exercises Option to License ChemoCentryx's ... (May '12) May '12 Robson 1
GlaxoSmithKline Exercises Option to License Che... (May '12) May '12 Joan 1
GSK obtains exclusive license to ChemoCentryx's... (May '12) May '12 Joan 1
Drug developer ChemoCentryx has priced its IPO ... (May '12) May '12 Joan 1
Market Report, "Diabetic Nephropathy - Pipeline... (May '12) May '12 Joan 1
More from around the web